Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neuroendocrine Tumors × sintilimab × Clear all

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Hepatocellular 13 Stomach Neoplasms 9 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 6 Rectal Neoplasms 5 Pancreatic Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Nasopharyngeal Carcinoma 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2 Turcot syndrome 1 Thyroid Neoplasms 1 Sarcoma 1 Salivary Gland Malignant Neoplasms 1 Rare Tumor 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasm Metastasis 1 NSCLC 1 Microsatellite Stable Metastatic Colorectal Cancer 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1 Meningeal Carcinomatosis 1 Lung Squamous Cell Carcinoma 1 Locally Recurrent Rectal Cancer 1 Locally Advanced or Metastatic Solid Tumors 1 Locally Advanced Rectal Cancer (LARC) 1

Interventions

lutetium Lu 177 dotatate 10 Everolimus 5 lanreotide 4 gallium Ga 68 dotatate 4 Magnetic Resonance Spectroscopy 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 olaparib 3 amino-acid, glucose, and electrolyte solution 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Cyclophosphamide 3 Capecitabine 3 surufatinib 2 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 copper dotatate CU-64 2 cabozantinib 2 Temozolomide 2 Specimen Handling 2 Octreotide 2 Lutetium 2 Injections 2 Fluorodeoxyglucose F18 2 talazoparib 1 sintilimab 1 repotrectinib 1 lenvatinib 1 guarana powder 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05165407 2025-03-14

NESSIE

Peking University

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡